A phase 1 trial of fusidic acid (CEM-102), an oral fusidane class antibiotic under development for treatment of gram-positive acute bacterial skin and skin structure infections, evaluating pharmacokinetics and safety is described. A randomized, double-blinded, placebo-controlled, dose escalation study was conducted in healthy adult subjects in the fasting state. Plasma exposure after multiple doses was higher than for single doses, indicating accumulation. Loading doses designed to optimize pharmacodynamic effects were well tolerated and achieved near-steady state concentrations of CEM-102 at 24 h. CEM-102 was safe and generally well tolerated at all single, multiple, and loading doses administered.
The emergence of resistance in Staphylococcus aureus to penicillinase-stable b-lactam drugs, most commonly referred to as methicillin-resistant S. aureus (MRSA), represents a major challenge for health care providers [1] [2] [3] [4] . The increasing prevalence and associated morbidity of hospital-acquired MRSA in the United States over the past 2 decades [2, [5] [6] [7] [8] [9] [10] and the more recent and widespread emergence of community-acquired MRSA infections [7, [11] [12] [13] [14] are well documented. The additional recognition of MRSA strains with decreased susceptibility or complete resistance to vancomycin [15, 16] and the increasing prevalence of multidrug-resistant staphylococci [3, 10, 17] , with limited oral treatment options, emphasize the critical need for effective alternative antimicrobials (ideally with new modes of action) for treatment of staphylococcal infections in hospitalized and community-based patients [18] .
Fusidic acid (or sodium fusidate), an antibiotic of the fusidane class that is primarily active against staphylococci, including MRSA, has been used in many Western countries and other parts of the world for .3 decades [19] [20] [21] [22] . Interest in the potential utility of fusidic acid in the treatment of MRSA infections in the United States has arisen because of its unique mechanism of action-specifically, inhibition of bacterial protein synthesis by binding to elongation factor G (EF-G) [23] -and by its lack of cross-resistance to other antimicrobial classes [24] . Despite its long history of use outside of the United States, resistance rates among clinical isolates of S. aureus are generally low, as supported by contemporary surveys. Fusidic acid exhibited potent activity (90% minimum inhibitory concentration [MIC 90 ], 0.12 lg/ml) and a low overall resistance rate (8.1%) when tested against 123 Canadian isolates collected during [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] ; by comparison, ciprofloxacin, clindamycin, and erythromycin resistance rates were 39%, 28%, and 47%, respectively [24] . Similar potency (MIC 90 , ,0.25 lg/ml) and low resistance rates were reported in another recent study of 272 Canadian isolates of MRSA, including macrolide-or ciprofloxacin-resistant staphylococci [25] . Among 3,135 staphylococci collected from 28 hospitals in 13 European countries in 2008, only 288 (10.6%) of 2700 S. aureus isolates displayed fusidic acid MIC values .2 lg/ mL, and in another survey, very low resistance rates (1%-3%) were observed in hospitals in Germany, Israel, Italy, Poland, Spain, and Sweden during 2008 [26] . A few countries, such as Australia (7%), Ireland (20%), and Greece (52%), have shown higher levels of S. aureus resistance to fusidic acid [26, 27] .
The labeled indications for oral sodium fusidate (Fucidin Ò , LEO Pharma) include treatment of skin and soft-tissue infections, osteomyelitis, and staphylococcal infections refractory to other antibiotic regimens [28] [29] [30] . Although the labeling specifies a dosage of 500 mg 3 times daily, sodium fusidate has been found to be equally effective and have fewer gastrointestinal adverse effects when administered in a 500-mg twice-daily regimen for treatment of skin and soft-tissue infections [31] [32] [33] [34] . Cempra has developed a new film-coated tablet of sodium fusidate (CEM-102) for twice-daily administration in efficacy trials. This report describes a study of the pharmacokinetics (PK), safety, and tolerability assessments of single doses of oral CEM-102, multiple doses, and loading-dose regimens in healthy adult subjects. Results of this study indicate that near-steady state plasma concentrations of CEM-102 are achievable within 24 h after administration of the first dose (1100 mg or 1650 mg) of a loading-dose regimen, and that front-loaded regimens may optimize the treatment of acute bacterial skin and skin structure infections (ABSSSI) due to MRSA.
METHODS

Study Populations
The study was conducted from October 2008 to April 2009 at Comprehensive Phase One (Miramar, FL). All study procedures were in accordance with the US Code of Federal Regulations, Title 21, parts 50, 56, and 312; with the ICH Guideline for Good Clinical Practice (E6); and with the most recent version of The Declaration of Helsinki [35] . Subjects were required to read, understand, and sign a written informed consent form after being apprised of the nature and purpose of the study, the conditions of participation and termination, and the potential risks and benefits of participating in the study.
A total of 40 healthy male and female subjects (age, 18-55 years) with a body mass index of 18-30 kg/m 2 and a total body weight .50 kg were enrolled in 5 cohorts (8 subjects per cohort) in the study. Pregnant or nursing women were excluded; otherwise, women of childbearing potential were required to be sexually inactive or to agree to use acceptable birth control methods 14 days before receipt of the first dose of study drug through 30 days after receipt of the last dose of study drug. Subjects enrolled had negative urine drug screen results and were willing to adhere to lifestyle guideline restrictions in the protocol. Subjects with electrocardiographic QTc values .450 msec for males and .470 msec for females were also excluded. Screening for eligibility occurred up to 3 weeks before dosing and enrolled subjects were admitted to the Clinical Research Unit (CRU) the day before dosing (Day -1) for each dosing period. Subjects were housed in the CRU for the duration of dosing and for 72 h after the last dose of study drug in each study period.
Study Design and Treatment Protocols
This was a randomized, double-blinded, dose-escalating, placebo-controlled study designed to evaluate (1) the PK, safety, and tolerability of escalating single and multiple doses of CEM-102; and (2) the PK, safety, and tolerability of loading doses of CEM-102, followed by lower maintenance doses, in fasting healthy adults. All doses of study drug administered consisted of film-coated tablets containing 275 mg of CEM-102 (sodium fusidate) or placebo (microcrystalline cellulose and anhydrous lactose; USP). The study was conducted in 2 periods. Period 1 assessed single-dose administration of CEM-102, Period 2 assessed multiple-dose administration, and Revised Period 2 assessed administration of a Day 1 loading dose followed by maintenance doses. In Period 1, subjects in cohorts 1-4 received a single dose of CEM-102 or placebo (550 mg, 1100 mg, 1650 mg, or 2200 mg) and remained in the CRU for 72 h after dosing for PK sampling and safety monitoring prior to discharge on Day 4. In Period 2, the subjects in Cohorts 1 to 3 were readmitted to the CRU after a 7 day washout period and received multiple doses of CEM-102 or placebo (same dose as in Period 1) every 12 h (Q12h) for 5.5 consecutive days (11 doses). These subjects remained in the CRU for 72 h after the last dose for PK and safety monitoring prior to discharge on Day 9.
Gastrointestinal intolerance (nausea and vomiting) was observed in 4 of the 5 subjects in cohort 3 after receipt of multiple 1650 mg doses; subjects in cohort 4 received only a single 2200-mg dose. These subjects returned for a Revised Period 2 in which they received a loading-dose regimen of CEM-102 or placebo (1100 mg Q12h on Day 1) followed by 550 mg Q12h maintenance doses for 6.5 days (13 doses). Subjects in a fifth cohort were enrolled directly into Revised Period 2 in which they received a loading dose regimen of 1650 mg Q12h (Day 1) followed by 825 mg Q12h maintenance doses for 6.5 days. Cohort 4 and 5 subjects remained in the CRU for an additional 72 h after dosing for PK and safety monitoring prior to discharge on day 11.
PK Assessments
Blood samples for assay of CEM-102 concentrations and PK analyses were collected before dosing and at frequent intervals after dosing, as shown in Table 1 . Plasma concentrations of CEM-102 were measured at MicroConstants (San Diego, CA) using a validated liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) method with a lower limit of quantitation of 20.0 ng/mL and a validation range of 20.0-50,000 ng/mL.
PK parameter estimates were derived from the plasma concentration versus time curves for a single dose of CEM-102 in Period 1, after 11 doses of CEM-102 on Day 6 in Period 2 (by which time steady state was reached), or after 15 doses on Day 8 in Revised Period 2. The estimates included maximum measured plasma concentration (C max ), measured concentration prior to (C pre ) and 12 h following (C post ) the 11th dose (Period 2) or 15 th dose (Revised Period 2), average concentration during a dosing interval at steady state (C avg ), area under the concentration versus time curve (AUC 0-t , AUC 0-tau , AUC 0-last , and AUC 0-inf ), the accumulation ratio (R acc ), time to peak concentration (t max ), apparent terminal elimination half-life (t 1/ 2 ), apparent first-order terminal elimination rate constant (K el ), apparent volume of distribution (V d /F), and apparent oral clearance (CL/F). Descriptive statistics, including arithmetic means, standard deviations, coefficients of variation (CV%), geometric means and median, and minimum and maximum values were calculated and summarized for each treatment group for measured PK parameters. Dose proportionality and linearity were assessed using graphical and statistical methods. Plasma CEM-102 concentrations were described by subject, scheduled time point, and cohort in tabular form and in concentration-time profiles for all regimens.
Safety Assessments
Evaluations of safety and tolerability included the following: physical examinations, vital signs, clinical laboratory parameters (blood chemical analyses, hematology and coagulation tests, and urinalysis) and standard 12 lead electrocardiograms before dosing, and during and/or following administration of study drug. Adverse events, graded by severity and categorized in relationship to drug exposure, were monitored throughout the study. A treatment-related adverse event was defined as any untoward medical occurrence in a subject considered by the clinical investigator to be related to CEM-102 and unrelated to a preexisting condition, unless the frequency, intensity, or character of this condition worsened during the course of the study. Clinically significant laboratory abnormalities were considered adverse events if they required medical or surgical intervention or led to study drug interruption or discontinuation.
Descriptive statistics including arithmetic mean, standard deviation, median, minimum, and maximum were calculated for quantitative safety determinations during and after treatment, including differences from baseline screening values. For categorical variables, descriptive statistics included counts and percentages per category. Adverse events were presented by severity, relationship to study drug, system organ class, preferred term, and dose level of study drug. Data from subjects who received placebo were pooled for analysis.
Sample Size
A sample size of 8 subjects per dosing cohort (6 CEM-102 and 2 placebo recipients) was considered adequate to characterize the PK of CEM-102 and to provide sufficient evidence of safety in this trial.
RESULTS
Study Population
This study enrolled 40 healthy subjects (21 men and 19 women). Demographic features were comparable among the CEM-102 and placebo groups. All subjects were included in the overall PK analysis and the safety analysis. Thirty-nine of 40 subjects enrolled completed the study protocol. One subject in the 550-mg CEM-102 multiple-dose group (Period 2) was withdrawn from the study at the discretion of the Investigator because of a persistently elevated serum creatine phosphokinase (CPK) level. Although this patient had a normal CPK level at screening, upon admission to the CRU for Period 1 his CPK level was elevated (413 U/L) and upon admission for Period 2 was also elevated (555 U/L). As these laboratory abnormalities were present prior to the administration of study drug, the Investigator did not feel this was related to fusidic acid administration. This subject was included in the safety and PK populations analyzed.
PK Results
PK parameter estimates for plasma samples collected and assayed in the study are presented in Tables 2-4 , and the mean concentrations of CEM-102 achieved in plasma over time after the administration of single-dose, multiple-dose, or loadingdose regimens to subjects in cohorts 1-5 are graphically displayed and compared in Figures 1 and 2 .
Period 1: Single Doses (Table 2 and Figure 1 ). Mean C max values increased from 32.6 lg/mL to 128.0 lg/mL in a dose-proportional manner over the range of 550 mg-2200 mg. Moderate variability in C max for all treatment cohorts was evident with a CV of 15%-32%. Median t max occurred at 2.0-6.0 h after receipt of single doses across all treatment groups. This range of t max was consistent across cohorts, suggesting a lack of significant variability of the rate of drug absorption. Exposure to single doses of CEM-102 as measured by AUC 0-12 , AUC 0-last , and AUC 0-inf increased in a dose-proportional manner up to 2200 mg. Variability in AUC 0-inf and AUC 0-last was moderate to high and ranged from 20.6% to 60.3% across cohorts. Estimates of mean CL/F for CEM-102 ranged from 1.0 L/h to 1.7 L/h over the single-dose range tested. The mean apparent volume of distribution (V z /F) for CEM-102 ranged from 17.9 to 32.6 L, suggesting significant distribution of this drug into peripheral tissues. Observed mean t 1/2 values were dose-independent and ranged from 12.3 to 16.1 h.
Period 2: Multiple Doses (Table 3 and Figure 1 ). Mean maximum concentrations of CEM-102 at steady state (C max,ss ) on Day 6 following 11 doses ranged from 130 lg/mL to 324 lg/mL in cohorts 1 to 3. Average concentration, C avg , ranged from 95.4 lg/mL to 274 lg/mL. CEM-102 C max,ss and C avg values increased in a dose proportional manner following multiple dose administration and variability of these parameters was moderate (CV range, 4.4%-37.8%). Median t max,ss occurred at approximately 3.0-4.0 h following multiple doses across all treatment groups; this range was consistent across cohorts and suggested a lack of significant NOTE. AUC, area under the concentration time curve; C avg , average concentration during a dosing interval at steady state; C max , maximum measured plasma concentration; C max,ss , maximum measured plasma concentration at steady state; CL ss/ F, apparent oral clearance at steady state; Racc, accumulation ratio; t max , time to peak concentration; t max,ss , time to peak concentration at steady state; t 1/2 , apparent terminal elimination half-life; V d,ss/ F, apparent volume of distribution at steady state.
a Data are mean (% coefficient of variation).
b Data are median (range).
variability of drug absorption. Exposure to CEM-102 as assessed by AUC 0-tau increased in a dose-proportional manner up to 1650 mg. The variability in AUC was moderate (CV range, 4.4%-37.8%) across cohorts. Estimates of mean apparent oral clearance at steady state (CL ss /F) ranged from .45 L/h to .55 L/h for multiple-dose administration and were consistent over the dose range tested; CL ss /F estimates for multiple dose administration were decreased by 50%-68%, compared with single-dose administration. Mean apparent volume of distribution at steady state (V d,ss /F) ranged from 10.5 L/h to 24.1 L/h after multipledose administration; these estimates were consistent over the dose range and were slightly lower than single-dose administration values. The mean t 1/2 of CEM-102 was independent of dose and ranged from 14.4 to 33.6 h over the dose range tested. Table 3 and Figure 1 demonstrate the significant accumulation of CEM-102 that occurred over the 5. (Tables 4 and 5 and Figure 2 ). In cohorts 4 and 5, a loading-dose strategy was implemented to achieve a therapeutic target range of CEM-102 more rapidly (80-100 lg/mL). After two loading doses of 1100 mg Q12h or 1650 mg Q12h, high plasma concentrations of CEM-102 were rapidly achieved. Plasma levels shown in Table 4 and Figure 2 were near-steady state concentrations after 24 h. Mean C max values at steady state on Day 8 were 144 lg/mL and 261 lg/mL for cohorts 4 and 5, respectively. In cohort 4 subjects, mean trough concentrations of CEM-102 were 74 lg/mL at 24 h and 101 lg/mL on Day 8 after a maintenance regimen of 500 mg Q12h (Table 5 and Figure 2 ). In cohort 5 subjects, mean trough concentrations were 146 lg/mL at 24 h and 204 lg/mL on Day 8 after a maintenance regimen of 825 mg Q12h (Table 5 , Figure 2 ).
Safety Results
Oral administration of single doses up to 2200 mg, multiple doses up to 1650 mg Q12h, and loading-dose regimens (Q12h on Day 1) followed by multiple Q12h doses of CEM-102 to healthy adults were safe and well tolerated at all dose levels evaluated. Adverse events were reported in 16 (53.3%) of 30 study subjects who received CEM-102 and 4 (40%) of 10 placebo subjects; most were considered mild in intensity. No deaths or serious adverse events were reported, and no subjects discontinued dosing due to an adverse event.
At the 2200-mg single-dose level, 2 of 6 subjects experienced nausea and 1 subject experienced nausea and vomiting. In Period 2, 2 subjects in the 550-mg multiple-dose group reported adverse events, whereas 5 of 6 subjects in the 1650-mg and 2200-mg dose groups experienced >1 adverse event, primarily related to mild gastrointestinal symptoms. The multiple-dose threshold for gastrointestinal intolerance was considered to be 1150-1650 mg, and escalation to the 2200-mg multiple-dose regimen was held. In Revised Period 2, loading-dose regimens were well tolerated, with only 1 subject in cohort 4 reporting a gastrointestinal adverse event (nausea); no gastrointestinal NOTE. AUC, area under the concentration time curve; C max , maximum measured plasma concentration; C max,ss , maximum measured plasma concentration at steady state; CL ss/ F, apparent oral clearance at steady state; t max , time to peak concentration; t max,ss , time to peak concentration at steady state; t 1/2 , apparent terminal elimination half-life; V d,ss/ F, apparent volume of distribution at steady state.
a Data are mean (%coefficient of variation). adverse events were reported in subjects in cohort 5. Therefore, loading-dose regimens followed by maintenance-dose regimens were considered safe and well tolerated up to a combination of 1650 mg/825 mg of CEM-102. No other clinically significant adverse events were reported at any dose level.
Laboratory Safety Evaluations
There were no clinically significant laboratory or electrocardiogram abnormalities reported for any dose level, regimen, or time point. No dose-related trends were observed for hematologic, coagulation, clinical chemistry, or urinalysis values. Transient, mild, and reversible increases in serum total bilirubin level (range, 1.3-2.2 mg/dL) were observed in 2 subjects who received multiple 1650-mg doses, in 2 subjects who received the 1100/550-mg loading-dose regimen, and in 4 subjects who received the 1650/825-mg loading-dose regimen. These abnormalities were not considered clinically significant.
DISCUSSION
Results of this phase 1 trial document the overall safety of single-, multiple-, and loading-dose regimens of CEM-102 in healthy adult subjects. These findings are consistent with the known safety of fusidic acid used in thrice-daily or twice-daily regimens outside of the United States for .40 years [20, 22] . Mild-tomoderate gastrointestinal intolerance observed at high doses is consistent with product information for fusidic acid from other countries; gastrointestinal reactions (eg, nausea, vomiting, epigastric pain, and anorexia, all of which have been reported to diminish with food intake) are the most common adverse events associated with oral fusidic acid, accounting for discontinuation of treatment of 1.7% of patients in registration trials [28, 29] . Mild and reversible elevations in the serum total bilirubin level observed at higher multiple-dose and loading-dose regimens of CEM-102 in healthy subjects in this study are also consistent with reports of reversible jaundice and elevated bilirubin level in recipients of multiple >500-mg oral doses of fusidic acid [31, 33] ; the mechanism for these reversible elevations in the bilirubin level has been described as direct inhibition of bile salt transport due to competitive interaction of fusidic acid with the transporter proteins multidrug resistance protein 2 (Mrp2) and bile salt export protein (Bsep) [36] . No electrocardiogram abnormalities were identified in this study, consistent with preclinical studies of CEM-102 showing weak inhibition of the human ether-à-go-go related gene channel and no adverse in vivo cardiovascular effects in animal safety pharmacology studies (Cempra Pharmaceuticals, data on file).
Published results have documented safety of oral fusidic acid at doses up to 4 g per day, when administered in divided doses, for the treatment of skin and skin-structure infections and for osteomyelitis, but limited available data document the safety, tolerance, and PK of single doses greater than 1000 mg. The safety and tolerance data obtained with singledose, multiple Q12h doses, and loading-dose regimens (up to 1650 mg Q12h on Day 1) of CEM-102 in this study provide support for a feasible front-loaded dosing strategy to optimize the PK of CEM-102 for treatment of ABSSSI, including those due to MRSA.
Exposure to CEM-102, as measured by AUC, increased in a dose-dependent manner following administration of escalating single or multiple doses. Plasma exposure was higher after receipt of multiple doses versus single doses, indicating drug accumulation over the treatment period, which was expected. The pharmacological basis for an apparent diminished clearance and accumulation of fusidic acid in multiple-dose regimens is not currently understood [37] . Front-loaded dosing regimens (1100 mg Q12h on Day 1, followed by 550 mg Q12h or 1650 mg on Day 1, followed by 825mg Q12h) were well tolerated and achieved high, near-steady state concentrations of CEM-102 within 24 h after administration of the first dose. In these loading-dose regimens, trough plasma concentrations increased gradually from 74 lg/mL on Day 1 to 101 lg/mL on Day 8 in subjects who received the 1100/550-mg regimen and from 146 lg/mL on Day 1 to 204 lg/mL on Day 8 in subjects who received the 1650/825-mg regimen (Table 5, Figure 2 ). These results indicate that a front-loading strategy is a viable approach to rapidly achieve and maintain high CEM-102 plasma concentrations at near-steady state levels across the dosing period without eliciting gastrointestinal intolerance or other adverse events. Figure 2 . Mean CEM-102 plasma concentrations after loading-dose followed by maintenance-dose regimens. As shown in the figure insert, subjects received the following during Revised Period 2: loading doses of 1100 mg every 12 h (Q12h) on Day 1 followed by maintenance doses of 550 mg Q12h (cohort 4) or loading doses of 1650 mg Q12h on Day 1 followed by maintenance doses of 825 mg Q12h (cohort 5).
Applications of in vitro pharmacodynamic and mechanismbased modeling support the benefit of front-loading regimens of CEM-102. Tsuji et al [38] demonstrated that the extent of bacterial killing (of MRSA) by simulated in vitro regimens of CEM-102 correlated well with total drug AUC 48 : MIC ratios. Front-loaded dosing regimens of CEM-102 that achieved a target AUC 48 : MIC ratio of .4 in that experimental system prevented the regrowth of MRSA that was observed with non-frontloaded regimens [39, 40] . Thus, trough concentrations of CEM-102 that reach near-steady state levels early in the course of treatment are needed to ensure adequate tissue exposure and clinical efficacy against highly resistant strains of S. aureus, coagulase-negative staphylococci, and many strains of Streptococcus pyogenes.
Optimization of fusidic acid PK is of critical importance in the context of the clinical management and emerging resistance patterns among MRSA and other staphylococcal pathogens [8, 18] . Optimized regimens need to achieve plasma concentrations several-fold that of the MIC 90 of gram-positive pathogens to provide sufficient free drug to obviate the high level of reversible protein-albumin binding of fusidic acid [37, [41] [42] [43] . Although serum proteins diminish the in vitro activity of CEM-102 for gram-positive pathogens, low pH (5.0-6.0) conditions, as found in purulent infection sites, may abrogate these protein binding effects [44] . Trough concentrations of CEM-102 that reach near-steady state levels early in the course of treatment should ensure adequate tissue exposure and clinical efficacy against even highly resistant strains of S. aureus, coagulase-negative staphylococci, and many strains of S. pyogenes. The loading-dose regimens were designed to achieve blood levels (see Figure 2 ) at least 10 times the MIC for ABSSSI organisms with lower susceptibilities than S. aureus, such as b-hemolytic streptococci. In recent surveys, MIC 90 values of 0.12, 16.0, and 8.0 lg/mL were reported for S. aureus, coagulase-negative staphylococci, and Streptococcus pyogenes isolates, respectively, receovered from Canadian hospitals [24] , and 288 (10.6%) of 2700 S. aureus strains from European hospitals displayed MICs >2 lg/mL. Genetic assessments of resistant S. aureus detected mutations on fusA (EF-G gene) including the common L461K alteration associated with fusidic acid MICs of >512 lg/mL [26] . Using front-loaded dosing regimens, it is possible to rapidly achieve and sustain trough concentrations at 10-64-fold the established breakpoints for S. aureus (EUCAST criteria; < 1lg/ mL) and enable alternative breakpoints for highly resistant species (eg, < 8 lg/mL). Moreover, previous determinations of in vitro mutation frequencies for resistance of S. aureus to fusidic acid [45] should be re-examined at higher drug exposure levels based on PK parameters achievable with front-loaded dosing regimens.
In conclusion, the results of this study demonstrate the ability to optimize the PK of fusidic acid to minimize potential for resistance development and to maximize the clinical management of ABSSSI due to gram-positive pathogens. 
